Acceptability No Is the option ○ acceptable to Probably no ○ key Uncertain ○ stakeholders? Probably yes ● Yes ○ Varies ○ Feasibility Is the option No ○ Probably no feasible to ○ implement? Uncertain ○ Probably yes ● Yes ○ Varies ○ Recommendation Should an alpha-2 agonist (e.g., dexmedetomidine) vs. no such strategy be used for patients WITHOUT delirium?
Acceptability Is the option acceptable to key stakeholders? ○ No ○ Probably no ○ Uncertain ● Probably yes ○ Yes ○ Varies Feasibility Is the option feasible to implement? ○ No ○ Probably no ○ Uncertain ● Probably yes ○ Yes ○ Varies Recommendation Should an alpha-2 agonist (e.g., dexmedetomidine) vs. no such strategy be used for patients WITHOUT delirium?
CCM_46_9_2018_06_08_DEVLIN_CCMED-D-18-00069_SDC26.docx